ACR RISE registry study looked at Rx of 3276 Sarcoidosis pts from 184 rheum practices finds 59.3% rx w/ steroids (24% prolonged steroids). and 12.1 Rx w/ biologics or tsDMARDs, mostly TNFi (inflx). But wide practice-level variations in Rx https://t.co/95CEDai2uN